Why Did Warren Buffett Buy Amazon Stock?
When investors think of tech stocks in Warren Buffett’s portfolio,…
Buy
53
RYTM Quote, Financials, Valuation and Earnings
Last price:
$63.25
Seasonality move
:
84.43%
Day range:
$61.17 - $62.43
52-week range:
$39.46 - $69.89
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
28.02x
P/B ratio:
208.62x
Volume:
694.5K
Avg. volume:
584.3K
1-year change:
48.39%
Market cap:
$4B
Revenue:
$130.1M
EPS (TTM):
-$2.81
Analysts' Opinion
-
Consensus RatingRhythm Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $83.42, Rhythm Pharmaceuticals has an estimated upside of 34.26% from its current price of $62.13.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $72.00 representing 100% downside risk from its current price of $62.13.
Fair Value
-
According to the consensus of 8 analysts, Rhythm Pharmaceuticals has 34.26% upside to fair value with a price target of $83.42 per share.
RYTM vs. S&P 500
-
Over the past 5 trading days, Rhythm Pharmaceuticals has underperformed the S&P 500 by -1.95% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Rhythm Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Rhythm Pharmaceuticals has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Rhythm Pharmaceuticals reported revenues of $32.7M.
Earnings Growth
-
Rhythm Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Rhythm Pharmaceuticals reported earnings per share of -$0.81.
Enterprise value:
3.8B
EV / Invested capital:
23.19x
Price / LTM sales:
28.02x
EV / EBIT:
--
EV / Revenue:
27.64x
PEG ratio (5yr expected):
-0.41x
EV / Free cash flow:
-33.33x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$122.7M
Return On Assets:
-47.31%
Net Income Margin (TTM):
-123.26%
Return On Equity:
-116.92%
Return On Invested Capital:
-116.92%
Operating Margin:
-143.73%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $33.6M | $91.9M | $136.9M | $26M | $32.7M | |
| Gross Profit | $30.3M | $81.2M | $122.7M | $23.2M | $29.1M | |
| Operating Income | -$179M | -$271.7M | -$172.6M | -$139.9M | -$47M | |
| EBITDA | -$170.5M | -$255.5M | -$146.3M | -$135.9M | -$43.6M | |
| Diluted EPS | -$3.35 | -$4.63 | -$2.81 | -$2.35 | -$0.81 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $412.1M | $253.4M | $317.8M | $235.8M | $369.3M | |
| Total Assets | $422.2M | $284.8M | $345.7M | $258.7M | $386.7M | |
| Current Liabilities | $16.9M | $47.3M | $46M | $54.2M | $111.8M | |
| Total Liabilities | $41.3M | $49.1M | $125.9M | $197.1M | $223.6M | |
| Total Equity | $380.9M | $235.8M | $219.8M | $61.6M | $163.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$156.2M | -$140.5M | -$113.5M | -$40.7M | -$40.4M | |
| Cash From Investing | -$26M | $5.9M | -$53.4M | $30.1M | $24.8M | |
| Cash From Financing | $213.3M | $78.7M | $219.5M | $4.2M | $32.5M | |
| Free Cash Flow | -$160.4M | -$180.5M | -$113.5M | -$80.7M | -$40.4M | |
RYTM
Sector
Market Cap
$4B
$32.8M
Price % of 52-Week High
88.9%
46.28%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
48.39%
-35.38%
Beta (5-Year)
2.301
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$62.59
200-day SMA
Buy
Level
$56.49
Bollinger Bands (100)
Buy
Level
53.77 - 63.29
Chaikin Money Flow
Buy
Level
62.1M
20-day SMA
Sell
Level
$63.36
Relative Strength Index (RSI14)
Sell
Level
48.12
ADX Line
Sell
Level
12.14
Williams %R
Buy
Level
-84.4396
50-day SMA
Sell
Level
$62.23
MACD (12, 26)
Buy
Level
0.22
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Neutral
Level
119.5M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.5622)
Sell
CA Score
(Annual)
Level (-3.4835)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (4.2409)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Stock Forecast FAQ
In the current month, RYTM has received 8 Buy ratings 0 Hold ratings, and 0 Sell ratings. The RYTM average analyst price target in the past 3 months is $83.42.
-
Where Will Rhythm Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Rhythm Pharmaceuticals share price will rise to $83.42 per share over the next 12 months.
-
What Do Analysts Say About Rhythm Pharmaceuticals?
Analysts are divided on their view about Rhythm Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Rhythm Pharmaceuticals is a Sell and believe this share price will drop from its current level to $72.00.
-
What Is Rhythm Pharmaceuticals's Price Target?
The price target for Rhythm Pharmaceuticals over the next 1-year time period is forecast to be $83.42 according to 8 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is RYTM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Rhythm Pharmaceuticals is a Buy. 8 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RYTM?
You can purchase shares of Rhythm Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Rhythm Pharmaceuticals shares.
-
What Is The Rhythm Pharmaceuticals Share Price Today?
Rhythm Pharmaceuticals was last trading at $63.25 per share. This represents the most recent stock quote for Rhythm Pharmaceuticals. Yesterday, Rhythm Pharmaceuticals closed at $62.13 per share.
-
How To Buy Rhythm Pharmaceuticals Stock Online?
In order to purchase Rhythm Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will RocketLab Stock Be In 5 Years?
Rocket Lab (NASDAQ: RKLB) closed recently at around $30 per share,…
Is MO dividend Worth It?
Altria Group (NYSE: MO) is paying investors $1.02 a share…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 41x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
88
CDTX alert for Jun 24
Cidara Therapeutics [CDTX] is up 3.18% over the past day.
Sell
46
HIMS alert for Jun 24
Hims & Hers Health [HIMS] is up 2.26% over the past day.
Buy
67
WGS alert for Jun 24
GeneDx Holdings [WGS] is up 13.99% over the past day.
